Stock Events

Stock Events

Kezar Life Sciences 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2KZ.MU. It's not an investment recommendation.
Apple
7
AAPL
Realty Income
6
O
Tesla
6
TSLA
Amazon
6
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical focuses on enzyme replacement therapies, directly competing in the rare disease space similar to Kezar's focus.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals targets cystic fibrosis and other rare diseases, overlapping with Kezar's therapeutic areas.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals specializes in RNAi therapeutics for rare genetic diseases, competing in the same niche as Kezar.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is involved in gene editing for rare diseases, representing direct competition in innovative treatments.
Novartis
NVS
Mkt Cap292.35B
Novartis AG has a broad portfolio including treatments for autoimmune diseases and rare conditions, competing across several of Kezar's interest areas.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on neurology and rare diseases, areas where Kezar Life Sciences is also aiming to develop treatments.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences has a diverse portfolio including oncology and inflammatory diseases, directly competing with Kezar's research focus.
AMGEN
AMGN
Mkt Cap233.78B
Amgen has a broad focus including treatments for cancer and autoimmune diseases, overlapping with Kezar's therapeutic areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is known for its innovative treatments in areas like oncology and rare diseases, competing with Kezar's development pipeline.

About

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Show more...
CEO
Dr. Christopher J. Kirk Ph.D.
Employees
58
Country
United States
ISIN
US49372L1008
WKN
000A40NJT

Listings

MU
DE
2KZ.MU
XNAS
US
KZR
BOATS
BOATS
KZR.BOATS

0 Comments

Share your thoughts

FAQ

What is Kezar Life Sciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Kezar Life Sciences stocks are traded under the ticker 2KZ.MU.
How many employees does Kezar Life Sciences have?▼
As of September 04, 2026, the company has 58 employees.
In which sector is Kezar Life Sciences located?▼
Kezar Life Sciences operates in the Health & Wellness sector.
When did Kezar Life Sciences complete a stock split?▼
The last stock split for Kezar Life Sciences was on October 30, 2024 with a ratio of 1:10.
Where is Kezar Life Sciences headquartered?▼
Kezar Life Sciences is headquartered in South San Francisco, United States.